Palynziq Market Report 2026

Palynziq Market Overview

• The Palynziq market growth in the historic period has been driven by improved diagnosis of phenylketonuria, clinical success of enzyme substitution therapies • Market expansion is supported by growing investments in rare disease drug development, expansion of newborn screening programs • Growth Driver: Rising Genetic Disorder Awareness Drives Growth In The Market • Market Trend: Advancing Drug Formulations With Long-Term Study To Optimize Safety And Treatment Outcomes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Palynziq Market?

Palynziq refers to the brand name for the medication pegvaliase-pqpz, a biologic drug used in the treatment of phenylketonuria (PKU), a rare genetic disorder characterized by an inability to metabolize phenylalanine, an amino acid found in food. It provides an enzyme that helps break down phenylalanine in the blood, thereby reducing its levels and preventing the neurological damage resulting from high phenylalanine concentrations. The main types of indications for palynziq include phenolketonuria (PKU) and other related metabolic disorders. Phenylketonuria (PKU) is a genetic metabolic disorder characterized by the inability to metabolize phenylalanine due to a deficiency of the enzyme phenylalanine hydroxylase. The distribution channels include pharmacies and online pharmacies for end users such as hospitals, specialty clinics, and home care settings.

What Is The Palynziq Market Growth Forecast?

The growth in the forecast period can be attributed to growing investments in rare disease drug development, expansion of newborn screening programs, increasing adoption of lifelong PKU management strategies, rising reimbursement support for orphan drugs, advancement of enzyme engineering technologies. Major trends in the forecast period include increasing adoption of enzyme replacement therapies, rising focus on rare metabolic disorder treatments, expansion of personalized pku management, growing emphasis on long-term metabolic control, enhanced patient monitoring and support programs.

Global Palynziq Market Segmentation

1) By Indication: Phenylketonuria (PKU), Other Related Metabolic Disorders 2) By Distribution Channel: Pharmacies, Online Pharmacies 3) By End User: Hospitals, Specialty Clinics, Home Care Settings

What Is The Driver Of The Palynziq Market?

The growing awareness of genetic disorders is expected to propel the growth of the palynziq market going forward. Genetic disorders are a broad category of medical conditions caused by abnormalities in an individual's DNA, ranging from single-gene mutations to complex chromosomal alterations. The growing awareness of genetic disorders is attributed to factors such as increased accessibility to genetic testing through advancements in genomic sequencing, affordable at-home DNA testing kits, global health campaigns promoting early diagnosis and intervention, and the integration of genetic education into healthcare systems. The growing awareness of genetic disorders leads to a greater demand for treatments such as Palynziq as patients and healthcare providers become more informed about available options. For instance, in July 2025, according to the Adult Polyglucosan Body Disease (APBD) Research Foundation, a US-based nonprofit organization dedicated solely to advancing research, a recent study on 1,4-alpha-glucan branching enzyme 1 (GBE1)-related rare genetic diseases updated the global prevalence estimate from 1 in 325,000 in 2022 to 1 in 236,000 in 2025, suggesting about 34,000 people worldwide could be affected, reflecting improved detection and data on these rare disorders. Therefore, growing awareness of genetic disorders drives demand for the palynziq industry.

Key Players In The Global Palynziq Market

Major companies operating in the palynziq market are BioMarin Pharmaceutical Inc.

Global Palynziq Market Trends and Insights

Major companies operating in the Palynziq market are focusing on developing innovative solutions, such as expanded post-marketing surveillance (PMS) and late-stage clinical studies, to meet the rising demand for long-term drug safety monitoring, regulatory compliance, and evidence-based confidence in treatment outcomes for phenylketonuria (PKU). Post-marketing surveillance evaluates a therapy’s real-world safety and effectiveness beyond initial approval, providing broader clinical insights compared with pre-approval trials that involve smaller, controlled patient populations. For instance, in April 2025, BioMarin Pharmaceutical, a US-based pharmaceutical company, announced that the Phase 3 PEGASUS trial evaluating Palynziq (pegvaliase-pqpz), an innovative advancement, met its primary efficacy endpoint by demonstrating a statistically significant reduction in blood phenylalanine (Phe) levels in adolescents aged 12–17 with PKU compared to diet alone, reinforcing Palynziq’s long-term therapeutic value and supporting continued safety and efficacy monitoring through PMS research.

What Are Latest Mergers And Acquisitions In The Palynziq Market?

In November 2023, Elliott Investment Management L.P., a US-based investment company, acquired a stake in BioMarin Pharmaceutical for $1 billion. These acquisitions reflect a transition period and strategic reassessment for BioMarin, influenced by internal leadership changes and external investor engagement. BioMarin Pharmaceutical is a US-based biotechnology company specializing in rare and genetic disease therapies, including Palynziq.

Regional Insights

North America was the largest region in the palynziq market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Palynziq Market?

The palynziq market consists of sales of pre-filled syringes, treatment kits, multi-dose vials, patient kits (with accessories), and unit dose packs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Palynziq Market Report 2026?

The palynziq market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the palynziq industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.